These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25367596)

  • 1. Long-Term Impact of Different Immunosuppressive Drugs on QT and PR Intervals in Renal Transplant Patients.
    Ikitimur B; Cosansu K; Karadag B; Cakmak HA; Avci BK; Erturk E; Seyahi N; Ongen Z
    Ann Noninvasive Electrocardiol; 2015 Sep; 20(5):426-32. PubMed ID: 25367596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT intervals in patients receiving a renal transplant.
    Monfared A; Atrkar Roshan Z; Salari A; Asadi F; Lebadi M; Khosravi M; Besharati S
    Exp Clin Transplant; 2012 Apr; 10(2):105-9. PubMed ID: 22432752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report.
    Hodak SP; Moubarak JB; Rodriguez I; Gelfand MC; Alijani MR; Tracy CM
    Transplantation; 1998 Aug; 66(4):535-7. PubMed ID: 9734501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of maximum corrected QT and corrected QT dispersion in electrocardiography after kidney transplantation.
    Monfared A; Ghods AJ
    Iran J Kidney Dis; 2008 Apr; 2(2):95-8. PubMed ID: 19377216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
    Marcén R; Galeano C; Fernández-Rodriguez A; Jiménez-Alvaro S; Teruel JL; Rivera M; Burgos FJ; Quereda C
    Transplant Proc; 2010 Oct; 42(8):3055-7. PubMed ID: 20970609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT prolongation is an independent predictor of mortality in end-stage renal disease.
    Hage FG; de Mattos AM; Khamash H; Mehta S; Warnock D; Iskandrian AE
    Clin Cardiol; 2010 Jun; 33(6):361-6. PubMed ID: 20556806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function.
    Perrea DN; Moulakakis KG; Poulakou MV; Vlachos IS; Nikiteas N; Kostakis A
    Int Urol Nephrol; 2008; 40(2):521-7. PubMed ID: 17978855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of rs10918594 polymorphisms of nitric oxide synthase 1 adaptor protein (NOS1AP) with QTc interval prolongation during kidney transplantation.
    Kaczmarczyk M; Biernawska J; Zukowski M; Kotfis K; Zegan-Barańska M; Bińczak-Kuleta A; Ciechanowicz A; Brykczyński M; Bohatyrewicz R
    Transplant Proc; 2011 Oct; 43(8):2964-6. PubMed ID: 21996201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT interval prolongation in the patients receiving maintenance hemodialysis.
    Suzuki R; Tsumura K; Inoue T; Kishimoto H; Morii H
    Clin Nephrol; 1998 Apr; 49(4):240-4. PubMed ID: 9582555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation.
    Morales JM
    Kidney Int Suppl; 2002 Dec; (82):S81-7. PubMed ID: 12410861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and prognostic significance of QT prolongation in chronic renal failure patients.
    Voiculescu M; Ionescu C; Ismail G
    Rom J Intern Med; 2006; 44(4):407-17. PubMed ID: 18386617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
    Marcén R
    Drugs; 2009 Nov; 69(16):2227-43. PubMed ID: 19852526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of genetic and electrolyte abnormalities in prolonged QTc interval and sudden cardiac death in end-stage renal disease patients.
    Coll M; Ferrer-Costa C; Pich S; Allegue C; Rodrigo E; Fernández-Fresnedo G; Barreda P; Mates J; Martinez de Francisco AL; Ortega I; Iglesias A; Campuzano O; Salas E; Arias M; Brugada R
    PLoS One; 2018; 13(7):e0200756. PubMed ID: 30020974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review.
    Niemeijer MN; van den Berg ME; Eijgelsheim M; van Herpen G; Stricker BH; Kors JA; Rijnbeek PR
    Heart; 2014 Dec; 100(23):1831-6. PubMed ID: 25092875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodialysis increases QT(c) interval but not QT(c) dispersion in ESRD patients without manifest cardiac disease.
    Covic A; Diaconita M; Gusbeth-Tatomir P; Covic M; Botezan A; Ungureanu G; Goldsmith DJ
    Nephrol Dial Transplant; 2002 Dec; 17(12):2170-7. PubMed ID: 12454229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis in renal transplant recipients on various immunosuppressive regimens.
    Atasever A; Bacakoglu F; Toz H; Basoglu OK; Duman S; Basak K; Guzelant A; Sayiner A
    Nephrol Dial Transplant; 2005 Apr; 20(4):797-802. PubMed ID: 15703207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.